NEW YORK (GenomeWeb) – Quidel announced after the close of the market Tuesday that it received 510(k) clearance from the US Food and Drug Administration to market the Solana Strep Complete Assay for rapid and qualitative detection and differentiation of Streptococcus pyogenes (Group A beta-hemolytic Streptococcus) and Streptococcus dysgalactiae (pyogenic Group C and G beta-hemolytic Streptococcus).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.